| Literature DB >> 34026618 |
Laura Van Gerven1,2,3, Zhen Qian1, Anastasiya Starovoyt2, Mark Jorissen1, Jeroen Meulemans1,4, Johannes van Loon5, Steven De Vleeschouwer5, Julie Lambert6, Marie Bex7, Vincent Vander Poorten1,4.
Abstract
BACKGROUND: The endoscopic endonasal transsphenoidal approach (EETA) is an established technique for the resection of a large variety of benign sellar and suprasellar lesions, mostly pituitary adenomas. It has clear advantages over the microscopic approach, like a superior close-up view of the relevant anatomy and the tumor-gland interface, an enlarged working angle, as well as an increased panoramic vision inside the surgical area. We have been performing the EETA for over a decade, and this study will focus on perioperative and postoperative outcomes and complications and their association with the learning curve.Entities:
Keywords: cerebrospinal fluid (CSF) leak; endoscopic endonasal surgery (EES); pituitary adenoma; pituitary tumor; transsphenoidal approaches
Year: 2021 PMID: 34026618 PMCID: PMC8138557 DOI: 10.3389/fonc.2021.643550
Source DB: PubMed Journal: Front Oncol ISSN: 2234-943X Impact factor: 6.244
Figure 1Flow diagram of the patient inclusion process. The patients were initially identified using two search queries: ‘‘Transsphenoidal pituitary surgery’’ ‘‘Transsphenoidal’’ in 2 databases; 1 was the billing file, the other the medical records. Afterwards, all of the unique patients were screened for the inclusion criteria. Note that at our hospital we do not have a separate code for CSF leak closure. Finally 369 unique patients were included in this study.
General patient demographics.
| Patient demographics | |||
|---|---|---|---|
| Number of patients | % | ||
| Female | 200 | 54.2 | |
| Median age—year | 50.0 | ||
| Range | 4–89 | ||
| Median follow-up duration—months | 55,0 | ||
| Range | 12–142 | ||
| Pathology | |||
| Pituitary adenoma | 322 |
| |
| Non-hormone expressing adenoma | 117 | 31.7 | |
| Corticotroph adenoma | 71 | 19.2 | |
| Somatotroph adenoma | 70 | 19.0 | |
| Gonadotroph adenoma | 21 | 5.7 | |
| Lactotroph adenoma | 14 | 3.8 | |
| Thyrotroph adenoma | 3 | 0.8 | |
| Plurihormonal adenoma | 26 | 7.0 | |
| Rathke cleft cyst | 19 | ||
| Craniopharyngioma | 9 |
| |
| Other | 19 |
| |
| Smoking | 146 | 39.6 | |
| Active | 73 | 19.8 | |
| Median pack–years | 15,0 | ||
| Range | 1–200 | ||
| Comorbidities | 263 | 71.3 | |
| Cardiovascular | 231 | 62.6 | |
| Obesity | 154 | 41.7 | |
| Diabetes mellitus | 56 | 15.2 | |
| Renal | 24 | 6.5 | |
| Respiratory | 17 | 4.6 | |
| Multimorbidity | 73 | 19.8 | |
General demographics of the included patients.
Median pack–years are calculated for the active and non-active smokers. Cardiovascular comorbidities mainly include hypertension and hypercholesterolemia. Diabetes mellitus includes type I and type II. Renal comorbidities include chronic kidney disease and dialysis. Respiratory comorbidities include asthma, COPD, and interstitial lung diseases.
Bold values are used to highlight the main groups.
Presurgical signs and biochemical evaluation.
| Presurgical signs and symptoms and biochemical evaluation | ||||
|---|---|---|---|---|
| All | Pituitary adenoma | |||
| N | % | N | % | |
|
| 227 | 61.5 | 185 | 57.3 |
| Headache | 160 | 43.4 | 127 | 39.3 |
| Typical visual field defect | 108 | 29.3 | 83 | 25.8 |
|
| 192 | 52.0 | 172 | 53.4 |
| Partial pituitary insufficiency | 65 | 17.6 | 59 | 18.3 |
| Panhypopituitarism | 72 | 19.5 | 58 | 18.0 |
| Partial pituitary insufficiency + hormone excess | 53 | 14.4 | 53 | 16.5 |
| Panhypopituitarism + hyperfunction | 2 | 0.5 | 2 | 0.6 |
|
| 264 | 71.5 | 238 | 74.0 |
| ACTH | 65 | 17.3 | 65 | 20.2 |
| TSH | 4 | 0.8 | 3 | 0.9 |
| GH | 61 | 16.5 | 61 | 18.9 |
| PRL | 17 | 4.3 | 17 | 5.3 |
| Disconnection hyperprolactinaemia | 91 | 24.7 | 66 | 20.4 |
| ACTH + Stalk effect | 4 | 1.1 | 4 | 1.2 |
| TSH + Stalk effect | 1 | 0.3 | 1 | 0.3 |
| Mixed GH + TSH | 1 | 0.3 | 1 | 0.3 |
| GH + Stalk effect | 6 | 1.6 | 6 | 1.9 |
| Mixed GH + PRL | 14 | 3.8 | 14 | 4.3 |
Figure 2Distribution of pituitary adenomas according to (A) size (micro < 10 mm; macro 10–40 mm; giant > 40 mm), (B) Knosp classification-grade, (C) main hormone expression pattern.
Perioperative and postoperative complications in relation to the pathology treated.
| All | Pituitary adenoma | Rathke cleft cyst | Craniopharyngioma | Other | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median operation duration—minutes | 88,0 | 88,5 | 66,0 | 114 | 92 | |||||
|
| 20–710 | 25–338 | 40–126 | 59–229 | 20-710 | |||||
|
| 73 | 19.8% | 59 | 18.3% | 4 | 19% | 6 | 66.7% | 4 | 23.5% |
| Perioperative CSF-leakage | 68 | 18.4% | 55 | 17.1% | 4 | 19% | 5 | 55.6% | 4 | 23.5% |
| Cavernous sinus hemorrhage | 2 | 0.5% | 2 | 0.6% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Carotid artery hemorrhage | 3 | 0.8% | 2 | 0.6% | 0 | 0.0% | 1 | 11.1% | 0 | 0.0% |
|
| ||||||||||
| Postoperative CSF-leakage | 27 | 7.3% | 19 | 5.9% | 5 | 23.8% | 3 | 33.3% | 0 | 0.0% |
| Diabetes insipidus | ||||||||||
|
| 42 | 11.4% | 42 | 13.0% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
|
| 37 | 10.0% | 22 | 6.8% | 9 | 42.9% | 5 | 55.6% | 1 | 5.9% |
| SIADH | 17 | 4.6% | 17 | 5.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Infections | 9 | 2.4% | 6 | 1.9% | 2 | 9.5% | 1 | 11.1% | 0 | 0.0% |
| Nasal obstruction | 33 | 8.9% | 26 | 8.1% | 4 | 19% | 0 | 0.0% | 3 | 17.6 |
| Cranial nerve damage | 6 | 1.6% | 5 | 1.6% | 0 | 0.0% | 0 | 0.0% | 1 | 5.9% |
| Intracranial hemorrhage | 3 | 0.8% | 3 | 0.9% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Intracranial hemorrhage and cerebral ischemia | 1 | 0.3% | 1 | 0.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
| Cavernous sinus hemorrhage | 1 | 0.3% | 1 | 0.3% | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% |
Recurrence rates and interventions in relation to the pathology treated.
| Recurrence rate | |||||||
|---|---|---|---|---|---|---|---|
| Total | Surgical reintervention | Other interventions* | |||||
| Pituitary adenoma | 62 | 19.3% | 24 | 7.5% | 38 | 11.8% | |
| Non-hormone expressing adenoma | 15 | 12.8% | 8 | 6.8% | 7 | 6.0% | |
| Corticotroph adenoma | 12 | 16.9% | 7 | 9.9% | 5 | 7.0% | |
| Somatotroph adenoma | 19 | 27.1% | 4 | 5.7% | 15 | 21.4% | |
| Gonadotroph adenoma | 3 | 14.3% | 2 | 9.5% | 1 | 4.8% | |
| Lactotroph adenoma | 4 | 28.6% | 1 | 7.1% | 3 | 21.4% | |
| Thyrotroph adenoma | 0 | 0.0% | 0 | 0.0% | 0 | 0.0% | |
| Plurihormonal adenoma | 9 | 34.6% | 2 | 7.7% | 7 | 26.9% | |
| Rathke cleft cyst | 3 | 17.6% | 3 | 17.6% | 0 | 0.0% | |
| Craniopharyngioma | 2 | 22.2% | 1 | 11.1% | 1 | 11.1% | |
| Others | 16 | 94% | 9 | 53% | 7 | 41.2% | |
*”Other interventions” are radiotherapy and hormonal suppression therapy.
Figure 3(A) Kaplan–Meier recurrence-free interval curves for the three most frequent histological types. (B) Kaplan–Meier recurrence-free interval curves for the pituitary adenomas operated during the first 5 years in comparison to the last 5 years.